Clinical Trials Logo

Clinical Trial Summary

Phenylketonuria (PKU) is a metabolic disease of genetic origin. This is a rare disease (incidence 1 / 16000 births) which is the subject of a systematic neonatal screening in France, because it is treatable by a diet low in phenylalanine. This plan is required upon confirmation of diagnosis and continued until the age of 8 years. The current trend is to continue the scheme at least until adolescence. Unlike other countries, in France there are no recommendations for a plan "for life". Knowledge about the natural history of PKU in adulthood, the effects of pediatric age, the frequency of complicated shapes, and prognostic factors are poorly documented. On the other hand, there is no consensus on the therapeutic management of this disease in adulthood and monitoring that could be directed towards the detection of neurological disorders and nutrition. Social integration and quality of life of adults PKU patients living in France have not been studied.


Clinical Trial Description

The aim off this study is to follow a French cohort of young adult patients with PKU to: - Describe the evolution of the disease in adulthood and neurological complications associated neuropsychological detect, investigate the prognostic factors for complications - Describe the metabolic balance of patients - Collect data on nutritional status, - Detect osteoporosis - Studying social integration and quality of life of adult patients with PKU - Collect biological samples for further study (markers of bone turnover) Design: Cohort : Duration of the inclusion period: 2 years Duration of subject participation: 5 years Total duration of the study: 7 years JUDGING CRITERIA: - Complications associated with PKU in adult - Evolution of neuropsychometric scores - Bone mineral density by densitometry - Measuring the quality of life of patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01619722
Study type Observational
Source University Hospital, Tours
Contact
Status Completed
Phase
Start date March 15, 2012
Completion date July 6, 2020

See also
  Status Clinical Trial Phase
Completed NCT02212288 - Antioxidant Signature in Adult Patients With Phenylketonuria Phase 4
Completed NCT05062226 - GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR N/A
Terminated NCT01904708 - Moderate Intensity Exercise and Phenylketonuria N/A
Completed NCT03913156 - Feeding Patterns and Practices in Young Children With PKU During the First Two Years of Life N/A
Recruiting NCT05051657 - Evaluation of the Express Plus Range N/A
Completed NCT04309331 - Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute N/A
Completed NCT04679467 - Evaluation of PKU Sphere in Italy N/A
Recruiting NCT05995717 - Evaluation of PKU UP N/A
Completed NCT04318509 - Market Research - Acceptability Study for a New PKU Protein Substitute N/A
Withdrawn NCT01412437 - Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria N/A
Terminated NCT04768348 - Natural History Clinical Study in Adult PKU